Comparative real-world effectiveness and safety of benralizumab and two mepolizumab dosing regimens in eosinophilic granulomatosis with polyangiitis: a 24-month prospective single-center cohort study

• by Marta Codirenzi, Federica Davanzo, Luca Iorio, Eleonora Fiorin, Gabriella Guarnieri, Fulvia Chieco Bianchi, Alessia Achille, Maria Rita Marchi, Andrea Vianello, Andrea Doria, Roberta Ramonda, Roberto Padoan

• June 15, 2026

Network meta-analysis of novel diagnostic biomarkers for rheumatoid arthritis: comparative performance of anti-CarP, anti-MCV, and emerging markers

• by Guanghui Li, Limin Tan, Jiayan Liu, Manxiang Wang

• June 16, 2026

Medical Oddities: The Economics of Shut-Eye

Sleep became a commodity, tea became a therapy, and cats got a reprieve this week.

• by Teraya Smith

• June 11, 2026

• 6 min

Trial Exclusions May Skew RA Drug Comparisons

Nearly 40% of registry patients would have been excluded from phase 3 randomized controlled trials, with exclusion criteria distributed unevenly across drug classes.

• by Andrea Surnit

• June 12, 2026

• 5 min